Summary
The pharmacokinetics of ketanserin and its main metabolite ketanserin-ol, and the antihypertensive effects of intravenous, single oral and chronic oral (40 mg once daily) administration of ketanserin, have been investigated in a single blind study of 10 patients with uncomplicated mild hypertension. Ketanserin had a terminal half-life of 29.2 h, a plasma clearance of 518 ml/min and a volume of distribution of 18.0 l/kg. Chronic oral intake of 40 mg ketanserin (tablet formulation) gave a peak concentration of unchanged ketanserin of 88 ng/ml after 1.1 h. Its absolute bioavailability was 48%.
During chronic therapy the maximal concentration of ketanserin-ol was 208 ng/ml and its half-life of elimination was 35.0 h. As this metabolite can be oxidized back to ketanserin, it contributes to the prolonged half-life of unchanged ketanserin seen during chronic therapy.
The blood pressure was reduced by approximately 15% by oral ketanserin. The maximal reduction in blood pressure coincided with the peak concentration of unchanged ketanserin. During chronic therapy with 40 mg once daily blood pressure was reduced over 24 h. The heart rate was slightly reduced and the cardiovascular responses and the plasma noradrenaline concentrations during isometric exercise were only slightly influenced by ketanserin therapy.
Thus, unchanged ketanserin has a relatively long half-life during chronic oral therapy and its pharmacokinetics in middle-aged hypertensive patients is similar to that in normal young volunteers.
Similar content being viewed by others
References
Janssen PAJ (1985) Pharmacology of potent and selective S2-serotoninergic antagonists. J Cardiovasc Pharmacol 7 [Suppl 7]: S2-S11
Van Nueten J, Janssen PAJ, Van Beek J, Xhonneux R, Verbeuren T, Vanhoutte P (1981) Vascular effects of ketanserin (R 41 468), a novel antagonist of 5HT2-serotoninergic receptors. J Pharmacol Exp Ther 218: 217–230
Van Nueten JM, Vanhoutte PM (1984) Cardiovascular pharmacology of ketanserin. In: 3rd Internat Symp Mechanisms of Vasodilatation. Bioltheca Cardiol no 38. Karger, Basle, pp 222–233
Wenting GJ, Woittiez AJJ, Man in't Veld AJ, Schalekamp MADH (1984) 5-HT, alpha-adrenoceptors and blood pressure. Effects of ketanserin in essential hypertension and autonomic insufficiency. Hypertension 6: 100–109
De Clerck F, David JL, Janssen PAJ (1982) Inhibition of 5-hydroxytrypamine-induced and amplified human platelet aggregation by ketanserin (R 41 468), a selective 5-HT2-receptor antagonist. Agents Actions 12: 388–397
De Clerck F, Xhonneux B, Leysen J, Janssen PAJ (1984) Evidence for functional 5-HT2-receptor sites on human blood platelets. Biochem Pharmacol 33: 2807–2811
DeCree J, Leempoels J, Demoen B, Roels V, Verhaegen H (1985) Effect of ketanserin on the hyperreactivity of platelets to 5-hydroxytryptamine in patients with cardiovascular diseases. J Cardiovasc Pharmacol 7 [Suppl 7]: S26-S28
DeCree J, Verhaegen H, Symoens J (1981) Acute blood-pressure-lowering effect of ketanserin. Lancet 1: 1161–1162
Wenting GJ, Man In't Veld AJ, Woittiez AJ, Boomsma F, Schaelekamp MADH (1982) Treatment of hypertension with ketanserin, a new selective 5-HT2-receptor antagonist. Br Med J 284: 537–539
Persson B, Hedner T, Berglund G (1983) Ketanserin in essential hypertension: effects during rest and exercise. Eur J Clin Pharmacol 25: 307–312
Hedner T, Persson B, Berglund G (1983) Ketanserin, a novel 5-hydroxytryptamine antagonist: Monotherapy in essential hypertension. Br J Clin Pharmacol 16: 121–125
Hedner T, Persson B, Berglund G (1985) A comparative and long-term evaluation of ketanserin in the treatment of essential hypertension. J Cardiovasc Pharmacol 7 [Suppl 7]: S148-S153
Wing LMH, Chalmers JP, West MJ, Bane AJ, Ayres B, Graham JR (1984) The effect of ketanserin on blood pressure and biochemical parameters in treated patients with essential hypertension. Clin Exp Hypertens A6: 1107–1117
Hedner T, Persson B (1984) Ketanserin in combination with β-adrenergic blocking agents in the treatment of essential hypertension. Br J Clin Pharmacol 18: 765–771
Reimann IW, Okonkwo PO, Klotz U (1983) Pharmacokinetics of ketanserin in man. Eur J Clin Pharmacol 25: 73–76
Heykants J, van Peer A, Woestenborghs R, Gould S, Mills J (1986) Pharmacokinetics of ketanserin and its metabolite ketanserin-ol in man after intravenous, intramuscular and oral administration. Eur J Clin Pharmacol 31: 343–350
Kurowski M (1985) Bioavailability and pharmacokinetics of ketanserin in elderly subjects. Eur J Clin Pharmacol 28: 411–417
Nyberg G (1977) Indirect blood pressure and heart rate measured quickly without observer bias using a semiautomatic machine (Auto-Manometer) — response to isometric exercise in normally healthy males and its modification by β-adrenoceptor blockade. Br J Clin Pharmacol 4: 275–281
Hjemdahl P, Daleskog M, Kahan T (1979) Determination of plasma catecholamines by high performance liquid chromatography with electrochemical determination. Life Sci 25: 131–138
Okonkwo PO, Reimann IW, Woestenborghs R, Klotz U (1983) High performance liquid chromatographic assay, with fluorometric detection of ketanserin, a new antihypertensive agent and serotonin S2-antagonist in human plasma, blood and urine. J Chromatogr 272: 411–416
Sheiner LB, Beal SL (1985) Pharmacokinetic parameter estimates from several least squares procedures: Superiority of extended least squares. J Pharmacokinet Biopharm 13: 185–201
Gibaldi M, Perrier D (1982) Pharmacokinetics (2nd edn). Marcel Dekker, New York
Genest J, Koiw E, Kuchel O (1977) Hypertension. Physiopathology and treatment. McGraw-Hill, New York
Frenken M, Kaumann A (1984) Interaction of ketanserin and its metabolite ketanserin-ol with 5HT2-receptors in pulmonary and coronary arteries of calf. Naunyn Schmiedebergs Arch Pharmacol 326: 334–339
Van Peer A, Woestenborghs R, Embrecht L, Heykants J (1986) Pharmacokinetic approach to equilibrium between ketanserin and ketanserin-ol. Eur J Clin Pharmacol 31: 339–342
Hedner T, Pettersson A, Gradin K, Persson B (1986) Peripheral serotoninergic mechanisms in cardiovascular regulation in the SHR. J Hypertens 4 [Suppl 3]: 223–225
DeCree J, Hoing M, de Ryck M, Symoens J (1985) The acute antihypertensive effect of ketanserin increases with age. J Cardiovasc Pharmacol 7 [Suppl 7]: S126-S127
Symoens J, Vanhoutte PM (1985) Role of serotonin in blood pressure regulation. In: Smith JAR, Watkins J, editors: Care of the postoperative surgical patient. Butterworth, London, pp 141–164
Pettersson A, Gradin K, Hedner T, Persson B (1985) Anti-hypertensive mechanism of action of ketanserin and some ketanserin analogues in the spontaneously hypertensive rate. Naunyn Schmiedebergs Arch Pharmacol 329: 394–397
Ball SG, Robertson JIS (1985) Is there α-adrenergic blockade and/or serotonergic blockade during chronic ketanserin treatment? J Cardiovasc Pharmacol 7 [Suppl 7]: S120-S122
Hosie J, Gould S (1985) Does ketanserin have a first dose effect in hypertension. Br J Clin Pharmacol 20: 535P
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Persson, B., Pettersson, A. & Hedner, T. Pharmacokinetics of ketanserin in patients with essential hypertension. Eur J Clin Pharmacol 32, 259–265 (1987). https://doi.org/10.1007/BF00607573
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00607573